Search PubMed⌕ Search

Biomedical subjects

G Brooker

Publications and source records attributed to G Brooker.

At least 55 records · Page 3Linked to original sources

Diphtheria toxin prevents catecholamine desensitization of A431 human epidermoid carcinoma cells.

We proposed that a rapidly turning over protein, induced in response to catecholamine stimulation of C6-2B rat astrocytoma cells, inhibits subsequent hormonal activation of adenylate cyclase. Studies upon which our hypothesis is based and confirmatory work in a variety of other cell lines and in vivo have utilized actinomycin D and cycloheximide to inhibit RNA and protein synthesis, respectively. These inhibitors, however, are not specific and have been reported also to interfere with other cellular processes. Diphtheria toxin is a specific protein synthesis inhibitor that acts only by ADP-ribosylating elongation factor 2, thus preventing peptide chain elongation. We thus tested whether diphtheria toxin could prevent catecholamine-induced desensitization in A431 human epidermoid carcinoma cells. The toxin inhibited protein synthesis and altered the time course of isoproterenol-stimulated cAMP accumulation as did the less-specific protein synthesis inhibitor cycloheximide. Cellular cAMP content after a 30-min exposure to isoproterenol was similar in control and in toxin-treated cells. However, after 4 hr of treatment with isoproterenol, toxin-treated cells accumulated up to six times more cAMP than controls. When cells or cell-free adenylate cyclase preparations were rechallenged with agonists, toxin-mediated inhibition of protein synthesis prevented desensitization. These results show that diphtheria toxin, a specific inhibitor of protein synthesis, can interfere with the normal physiological regulation of cAMP metabolism in eukaryotic cells and provide compelling evidence that catecholamine stimulation of adenylate cyclase promotes the synthesis of a protein(s) that, in some way, inhibits hormone-stimulated adenylate cyclase.

Adenylyl Cyclases↗

Expression of rat mRNA coding for hormone-stimulated adenylate cyclase in Xenopus oocytes.

Beta-Adrenergic agonist-stimulated hyperpolarization, whole-cell cAMP accumulation, and activity of isoproterenol-stimulated membrane-bound adenylate cyclase (EC 4.6.1.1) in Xenopus laevis ovarian oocytes are entirely dependent on the presence of nascent follicle cells. A method was developed to remove rapidly and completely all extra-oocyte cell types to yield defolliculated oocytes that exhibited normal viability and resting membrane potentials yet lacked beta-adrenergic receptor (beta AR)-stimulated responses. Purified follicle membranes contained beta AR-stimulated adenylate cyclase activity, whereas oocyte cell membranes did not. Purified oocyte membrane preparations from X. laevis oocytes previously microinjected with C6-2B rat astrocytoma mRNA, and subsequently defolliculated, exhibited novel beta AR and forskolin-stimulated adenylate cyclase activity. These experiments demonstrate that oocytes expressed rat C6-2B mRNA coding for the beta-adrenergic receptor and the components necessary for forskolin-stimulated adenylate cyclase activity.

8-Bromo Cyclic Adenosine Monophosphate↗

Maintenance of whole cell isoproterenol and forskolin responsiveness in adenylate cyclase of permeabilized cells.

Digitonin-permeabilized monolayers of C6-2B rat astrocytoma cells exhibit adenylate cyclase activity in the presence of exogenously added ATP. The adenylate cyclase retains the qualitative and quantitative characteristics of hormone stimulated cyclic AMP accumulation in whole cells including GTP dependency and 100 fold stimulation by isoproterenol. Forskolin increased enzymatic activity in the absence of added GTP, however forskolin efficacy and potency was enhanced by GTP. Low non-efficacious concentrations of forskolin, without added GTP, supported isoproterenol-stimulated cyclase activity. The GTP-stimulated isoproterenol response was potentiated by forskolin. Forskolin support of isoproterenol stimulated cyclase in the absence of GTP raises the possibility that forskolin can act independently of GTP in coupling receptors to cyclase catalytic units and/or that forskolin could increase the efficacy and potency of GTP in the coupling reaction. Permeabilization of C6-2B and other cultured cells yields a preparation of adenylate cyclase which retains the enzyme in a state which closely approximates its activity in the native membrane--a system which could prove useful in studies of the regulation of adenylate cyclase in vivo.

Adenosine Triphosphate↗

Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling.

Forskolin directly stimulates adenylate cyclase activity and acts synergistically with receptor-mediated agonists which stimulate cyclic AMP production. We have previously observed that a 3-hr incubation of C6-2B rat astrocytoma cells with 6 nM cholera toxin in the presence of 1 microM forskolin results in cyclic AMP accumulation 9-fold greater than in the absence of forskolin. Since the action of cholera toxin is mediated by the stimulatory guanine nucleotide-binding regulatory component (GS) of the adenylate cyclase complex, we proposed that the mechanism by which forskolin augments hormone responses involves an enhanced coupling of GS with the adenylate cyclase catalytic component (C). In the present communication, we report the detailed characterization of the synergistic interaction between forskolin and cholera toxin as effectors of cyclic AMP accumulation in intact C6-2B cells. After a 3-hr incubation, maximal cholera toxin-stimulated cyclic AMP accumulation was 990 +/- 34 pmol/mg of protein. In the presence of 1 microM forskolin, the response to cholera toxin increased to 13,137 +/- 1,595 pmol of cyclic AMP/mg of protein. The half-maximally effective cholera toxin concentrations estimated by nonlinear least squares regression analysis determined in the absence or presence of 0.1 mM forskolin were 56.6 and 57.5 pM, respectively. The highly reproducible lag in forskolin-stimulated cyclic AMP accumulation in C6-2B cells was abolished by cholera toxin pretreatment, indicating a possible role for GS-associated GTPase in the mechanism of forskolin action. Cholera toxin treatment markedly augmented forskolin-stimulated cyclic AMP accumulation and shifted the forskolin concentration-response curve to the left approximately 1.5 log units. When C6-2B cells were treated for 1 min with 10 nM cholera toxin, the response to forskolin was significantly potentiated by 10 min. No significant increase in cellular cyclic AMP content in the absence of a forskolin challenge was apparent for up to 45 min. It appears that prior promotion of GS-C coupling by cholera toxin treatment enhances the ability of forskolin to stimulate cyclic AMP accumulation. Whether or not forskolin interacts (i.e., binds) exclusively to C remains to be proven. However, the actions of forskolin to stimulate cyclic AMP formation and potentiate agonist-stimulated cyclic AMP formation are modulated by the activity state of GS, and at least part of the response to forskolin is mediated by GS.

Adenosine Diphosphate Ribose↗

Dissociation of RNA synthesis from the calcium requirement for serum-increased ornithine decarboxylase activity in rat glioma cells.

When C6-2B rat glioma cells were stimulated with calf serum in the presence of calcium, ornithine decarboxylase activity increased maximally in 6-8 h after an initial 2-3 h lag period wherein RNA synthesis occurred. The increase of ornithine decarboxylase activity in serum-stimulated C6-2B cells was prevented by the calcium chelator EGTA, but EGTA had no effect upon RNA synthesis as judged by [3H]uridine incorporation into RNA. In addition, the calcium requirement for increased ornithine decarboxylase activity was temporally distal to the lag period. EGTA appeared to inhibit the synthesis of ornithine decarboxylase, because the half-life values of ornithine decarboxylase activity were similar (37-47 min) in the presence of EGTA or protein synthesis inhibitors such as cycloheximide or emetine. Also, calcium readdition rapidly reversed EGTA inhibition of ornithine decarboxylase activity by a mechanism which could be blocked by cycloheximide.

Animals↗

Calcium dependence for increased antizyme inhibitory activity of ornithine decarboxylase in rat glioma cells.

Ornithine decarboxylase activity was inhibited by the antizyme inhibitor protein in extracts from C6-2B rat glioma cells. Antizyme activity in C6-2B cells was increased 3- to 10-fold by micromolar concentrations of putrescine, spermidine and spermine. The calcium chelator EGTA (pCa 6.4) inhibited basal and polyamine-stimulated antizyme activity, and this inhibition was prevented by concurrent incubation with calcium, but not with magnesium. EGTA appeared to block antizyme synthesis, because the half-life values of antizyme activity in the presence of EGTA or cycloheximide were similar (121-143 min). Also, calcium readdition rapidly reversed EGTA inhibition of antizyme activity by a mechanism which could be blocked by cycloheximide. The ability of EGTA to inhibit spermidine-stimulated antizyme activity was not due to reduced spermidine uptake, because EGTA actually stimulated [3H]spermidine accumulation in the trichloroacetic acid-soluble fraction of C6-2B cells after 3 h.

Animals↗

Distinct mechanisms of forskolin-stimulated cyclic AMP accumulation and forskolin-potentiated hormone responses in C6-2B cells.

Forskolin activates a variety of adenylate cyclase systems and acts synergistically with receptor-mediated agonists which stimulate cyclic AMP production. The mechanism(s) and site(s) of forskolin action remain unclear. In C6-2B rat astrocytoma cells, forskolin stimulated greater than a 100-fold increase in cellular cyclic AMP content with a half-maximally effective concentration (EC50) of greater than 50 microM. Incubation of C6-2B cells with forskolin plus (-)-isoproterenol resulted in an increase in (-)-isoproterenol efficacy and potency. The EC50 for the forskolin-induced increase in (-)-isoproterenol potency was 22 nM, greater than 3 orders of magnitude lower than the EC50 for direct forskolin-stimulated cyclic AMP accumulation. Forskolin had no effect on beta-receptor affinity for (-)-isoproterenol as measured by competition for (-)-[125I]iodopindolol binding sites. Forskolin also augmented the responses to prostaglandin E1 and cholera toxin. Inhibition of protein synthesis with cycloheximide markedly reduced forskolin-stimulated cyclic AMP accumulation with little or no effect on the responses to (-)-isoproterenol, prostaglandin E1, or cholera toxin. The ability of forskolin to act synergistically with these agents was unaffected by cycloheximide treatment. These observations are compatible with a two-site model of forskolin action in C6-2B cells: a low-affinity site which mediates the direct action of forskolin to increase cellular cyclic AMP accumulation and a high-affinity site which mediates the potentiative action of forskolin. The low-affinity forskolin site appears to reside on a protein which is closely associated with the catalytic adenylate cyclase moiety and has a relatively shorter half-life than other components of the cyclase system. The high-affinity site resides on a more stable component of the adenylate cyclase system. The synergistic action of forskolin may involve an enhancement of the interaction between the guanine nucleotide-binding regulatory component and the catalytic component of the adenylate cyclase complex.

Adenylyl Cyclases↗

Selective reduction of forskolin-stimulated cyclic AMP accumulation by inhibitors of protein synthesis.

Inhibiting protein synthesis by incubating C6-2B rat astrocytoma cells with cycloheximide or emetine for periods up to 24 hours caused a progressive decrease in the accumulation of adenosine 3',5'-monophosphate (cyclic AMP) when the cells were challenged for 30 minutes with 100 microM forskolin. In contrast, cholera toxin-stimulated (6 nM, 3 hours) cyclic AMP accumulation was not diminished in cycloheximide-treated cells, and cyclic AMP was only minimally diminished in response to a 30-minute challenge with 10 microM (-)-isoproterenol. These experiments suggest the presence of a previously unrecognized cyclase component, which is essential for forskolin-stimulated cyclic AMP accumulation and has a shorter half-life than the beta-adrenergic receptor, the guanine nucleotide regulatory proteins, or the cyclase catalytic component.

Animals↗

Forskolin-stimulated cyclic AMP accumulation mediates protein synthesis-dependent refractoriness in C6-2B rat glioma cells.

We have examined the roles that cyclic AMP and protein synthesis play in the development of refractoriness in C6-2B rat glioma cells using the diterpene, forskolin, a general activator of cyclic AMP-generating systems. Forskolin-stimulated cyclic AMP accumulation peaked at 30 min and declined thereafter to 10% of peak levels by 3 hr despite the continued presence of sufficient forskolin to produce 98% of the control response when the incubation medium was transferred to naive cells. C6-2B cells treated for 3 hr with forskolin were refractory to a subsequent challenge with forskolin or isoproterenol. The phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) increased the degree of refractoriness developed after forskolin treatment. In the presence of IBMX, the induction of refractoriness by forskolin and forskolin-stimulated cyclic AMP accumulation were similarly dependent on forskolin concentration. Pre-treatment with isoproterenol or the cyclic AMP analogue, dibutyryl cyclic AMP, induced refractoriness to forskolin. When C6-2B cells were pre-treated with forskolin plus the protein synthesis inhibitor, cycloheximide, the development of refractoriness to forskolin or isoproterenol was attenuated. Cycloheximide prevented isoproterenol- or dibutyryl cyclic AMP-induced refractoriness to forskolin. These data provide further evidence that the onset of the refractory state in C6-2B cells is mediated by cyclic AMP and is a protein synthesis-requiring process.

1-Methyl-3-isobutylxanthine↗

Radioimmunoassay of digitonin.

We describe a radioimmunoassay for digitonin which utilizes the ability of digotonin to compete with 125I-labeled digoxigenin for binding to anti-digoxin antiserum. As performed using the Gammaflo automated radioimmunoassay system and commercially available reagents, the assay can detect as little as 20 micrograms/ml (15 microM) digitonin. The assay is insensitive to interference by cholesterol or other cell membrane constituents and is useable above and below the critical micelle concentration of digitonin. It should be useful for the monitoring of digitonin concentrations in solubilized biochemical preparations.

Animals↗

Evidence for persistent activation of cardiac slow channels in low-calcium solutions.

Action potentials were recorded from frog ventricular strips superfused with calcium-free solutions. Very long action potentials (3-60 s) were induced by chelating residual calcium with 1-5 mM ethyleneglycol-bis(beta-aminoethylether)-N,N'-tetraacetic acid (EGTA). The kinetics of changes in action potential duration suggest that calcium influences action potential duration at an intracellular site. In low-calcium solutions isoproterenol was found to lengthen action potentials. The lengthening effect of isoproterenol became progressively greater as [Ca2+] was reduced by elevating [EGTA]. In the presence of 2 mM EGTA, 0.1 microM isoproterenol increased action potential duration from 4.3 +/- 0.4 to 43 +/- 14 s. Verapamil produced a greater than 90% reduction in the duration of very long action potentials (60 s) induced by EGTA, isoproterenol, or both. After rapid or prolonged depolarizations in low-calcium solutions the last 10-30 mV of repolarization took 10-15 s. We speculate that this slow phase of repolarization may be a manifestation of persistent slow channel activation. The data suggest that in low-calcium solutions slow channels can remain activated for many seconds.

Action Potentials↗

Cycloheximide potentiation of prostaglandin E1- and cholera toxin-stimulated cyclic AMP accumulation in NG108-CC15 neuroblastoma-glioma hybrid cells.

Previous studies have demonstrated that catecholamine responsiveness in a variety of cells can be altered by inhibitors of RNA and protein synthesis. The neuroblastoma-glioma hybrid, NG108-CC15, which lacks catecholamine-stimulated accumulation of cyclic AMP, was investigated to determine if the responsiveness to prostaglandin E1 (PGE1) could be modified by inhibitors of protein synthesis. Cycloheximide in a time-dependent manner potentiated the ability of prostaglandin E1 to stimulate accumulation of intracellular cyclic AMP. However, the alpha-adrenergic inhibition of the prostaglandin response was not affected by cycloheximide. Withdrawal of norepinephrine following a long-term incubation resulted in a potentiation of subsequent PGE1-stimulated cyclic AMP accumulation. Cycloheximide enhanced this norepinephrine withdrawal effect. Our previous studies have shown that cholera toxin induces refractoriness to beta-adrenergic agonists in C6-2B rat astrocytoma cells and that cycloheximide blocked this action of cholera toxin. In an analogous manner cholera toxin caused refractoriness to subsequent prostaglandin-stimulated cyclic AMP production in NG108-CC15 cells, and cycloheximide reduced cholera toxin-induced prostaglandin refractoriness. Thus cycloheximide potentiates the prostaglandin stimulatory effect, has no effect on the ability of alpha-agonists to inhibit the prostaglandin response, increases the stimulatory effect of PGE1 after norepinephrine withdrawal, and reduces cholera toxin-induced PGE1 refractoriness. these observations suggest that PGE1-stimulated cyclic AMP accumulation in NG108-CC15 cells contains components which are regulated by de novo protein synthesis.

Animals↗

beta-Adrenergic blocking agents. alpha- and gamma-methyl(aryloxy)propanolamines.

A series of gamma-methyl- (5) and alpha-methyl(aryloxy)propanolamines (6) were synthesized and evaluated for beta-adrenergic blocking action. The binding constant (KD) was determined for compounds 5a-j on cultured C6-2B astrocytoma cells. Compounds 5a-j and 6a-e were evaluated for beta 1-antagonist action on guinea pig atria and beta 2-antagonist action on guinea pig tracheal strips. Several gamma-methyl(aryloxy)propanolamines showed affinity for beta receptors and a possible preference for beta 2 receptors.

Adrenergic beta-Antagonists↗

Potentiation of cholera toxin-stimulated cyclic AMP production in cultured cells by inhibitors of RNA and protein synthesis.

Cyclic AMP increased 8- to 10-fold after a 3-h treatment with 6 nM cholera toxin in rat C6-2B astrocytoma cells. In the presence of cycloheximide, cholera toxin increased intracellular cyclic AMP about 50-fold. Qualitatively similar potentiation of cholera toxin action by cycloheximide was observed in isolated swine aortic vascular smooth muscle cells. Cycloheximide, by itself, had no effect upon cyclic AMP levels and did not alter the apparent Ka for cyclic AMP generation by cholera toxin in the cells. Also, cycloheximide did not appear to augment cholera toxin action via inhibition of cyclic nucleotide phosphodiesterase. Puromycin and actinomycin D also augmented cholera toxin action in C6-2B cells. Potentiation of cholera toxin-increased cyclic AMP formation by cycloheximide was correlated with the inhibition of [14C]leucine incorporation into protein. These results indicate that the ability of cholera toxin to stimulate cyclic AMP production in C6-2B astrocytoma and swine vascular smooth muscle cells is enhanced by inhibition of de novo protein synthesis.

1-Methyl-3-isobutylxanthine↗

Calcium and microtubule dependence for increased ornithine decarboxylase activity stimulated by beta-adrenergic agonists, dibutyryl cyclic AMP, or serum in a rat astrocytoma cell line.

Ornithine decarboxylase (ODCase; L-ornithine carboxy-lyase; EC 4.1.1.17) activity was increased 5-20 fold above basal activity by N(6),O(2')-dibutyryl cyclic AMP, isoproterenol, epinephrine, or fetal calf serum in confluent C6-2B rat astrocytoma cells. Serum increased ODCase activity by a mechanism apparently independent of cyclic AMP because it decreased intracellular cyclic AMP. Calcium ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) buffers (pCa = 6.4) reduced basal ODCase activity and blocked the increase in activity by beta-adrenergic agonists, dibutyryl cyclic AMP, or serum. Readdition of calcium to pCa = 4.0 restored the ability of the cells to respond to these agents. The rise in ODCase activity stimulated by isoproterenol, dibutyryl cyclic AMP, or serum was also blocked by the microtubule disrupting agents, vinblastine and colchicine, and by the microfilament disrupting agent, cytochalasin B. Lumicolchicine, an analog of colchicine that does not disrupt microtubules, was ineffective. The microtubule and microfilament disrupting agents and EGTA had no effect on the intracellular accumulation of cyclic AMP. Cycloheximide inhibited protein synthesis >95% within 30 min, and caused an immediate decline of stimulated ODCase activity with a half-time of 20-30 min. The inhibition of ODCase activity by colchicine or EGTA was distinct from that seen with cycloheximide and could not be correlated to their effects on general protein synthesis. Colchicine or EGTA each caused identical rates of decline in ODCase activity with a half-time of 20-30 min after an initial lag period of about 60 min.

Adrenergic beta-Agonists↗